Clinical trial
Early Access of MK0518 in Combination With an Optimized Background…
NCT00377065 · Merck Sharp & Dohme LLC, Industry · Approved for marketing
Key facts
| NCT number | NCT00377065 |
|---|---|
| Title | Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) |
| Official title | Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | raltegravir |
| First posted | Sep 15, 2006 |
| Last update posted | Apr 22, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: